Prot#: ISIS 766720-CS2: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks i
- Huang, Wenyu (PD/PI)
- Molitch, Mark E (Other)
Project: Research project